Olink is developing a novel sequencing based proteomics platform. Their 2020 revenue was $54.1 million, 16.7% growth on 2019. This year growth looks se…
So Illumina are pushing forward with their GRAIL acquisition. It seems like a good time to review what (little) I know of the early stage cancer detect…
I was recently asked about Nooma Bio. This is a company and approach I’ve not looked at for some time. But it appears they published a couple of papers…
Solexa has come up in a few conversations recently. Obviously Solexa’s contribution to next-gen sequencing is difficult to ignore. But it’s also an int…
So it seems Twinstrand are suing Guardant over use of their duplex sequencing approach. This suggests that Guardant’s digital sequencing and Twinstrand…
Cees Dekker’s group recently published progress toward nanopore protein sequencing. The work addresses one of the fundamental issues in nanopore protei…
PacBio appear to be set to acquire Omniome for $600 million with an additional $200 million in milestone payments. Similar to Illumina’s proposed acqui…
Company Seer is a Proteomics sample prep company. They IPO’d earlier this year. Prior to that they appear to have raised $169.5M. Having been founded i…
I came across another patent from the Dreampore folks when investigating the platform, and thought it might be interesting to write up. It’s actually n…
Company Dreampore is a French Nanopore Protein sequencing company based in Paris. There’s not much information available on Dreampore, most of it comes…
I previously looked at QuantumSi’s protein sequencing approach back in September. But recently someone forwarded me their prospectus. Having recently r…
My previous post on Nautilus covered their published IP and was originally released to paid subscribers. After it was released publicly, someone forwar…